insights_auto
Prečo akcie LXRX klesli 4,55%?
Preskúmať podrobnejšiechevron_right
LXRX:NASDAQ
Lexicon Pharmaceuticals Inc
1,68 USD
arrow_downward
-4,55%(-0,080) 1 d.
1,70 USD
arrow_upward
+1,19% (+0,020)bedtimePo uzavretí
Zavreté: 9. 10., 16:00:01 GMT-4 · USD
search
Všetky symboly
| Symbol | Cena | Zmena | % zmeny |
|---|
insights_autoGenerujú sa najdôležitejšie štatistiky pre LXRX…
Otvoriť
1,75 USD
Vysoká
1,77 USD
Nízka
1,67 USD
Trh. kap.
747,53 mil.
Priem. obj.
3,08 mil.
Objem
2,07 mil.
Max. za 52 týž.
2,68 USD
Min. za 52 týž.
1,10 USD
Výnosy na akciu
-0,15 USD
Beta
1,36
Akcie v obehu
444,96 mil.
Počet zamestnancov
81
Otvoriť
1,75 USD
Vysoká
1,77 USD
Nízka
1,67 USD
Trh. kap.
747,53 mil.
Priem. obj.
3,08 mil.
Objem
2,07 mil.
Max. za 52 týž.
2,68 USD
Min. za 52 týž.
1,10 USD
Výnosy na akciu
-0,15 USD
Beta
1,36
Akcie v obehu
444,96 mil.
Počet zamestnancov
81
Spravodajstvo
Z internetových zdrojov a od spravodajských partnerov
TradingView
·
pred 48 minútami
Retension Pharmaceuticals, Clinical-Stage Developer of Hypertension Therapies, Files for Nasdaq Capital Market IPO
Yahoo Finance
·
pred 1 hodinou
Ruanyun Edai Technology Inc. Receives Nasdaq Minimum Bid Price Deficiency Notice
Quiver Quantitative
·
pred 1 hodinou
Axe Compute Inc. to Ring Nasdaq Opening Bell Amid AI Infrastructure Growth and $3.45 Billion in Signed Contracts
Seeking Alpha
·
pred 38 minútami
Depreciation Subtleties: S&P Earnings Are Vastly Overstated (NYSEARCA:SPY)
Profil
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its mouse gene knockout technology and in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 100 potential therapeutic targets. Lexicon has advanced multiple drug candidates into human clinical trials and has a broad and diverse pipeline of drug targets behind its clinical programs. Lexicon is pursuing drug targets in five therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology.
The company's clinical drug candidates include sotagliflozin for the treatment of type 2 diabetes; LX1033 for the treatment of irritable bowel syndrome and other gastrointestinal disorders; telotristat ethyl for the treatment of the symptoms associated with carcinoid syndrome; and LX2931 for the treatment of autoimmune diseases, such as rheumatoid arthritis. Wikipedia
Informácie o subjekte Lexicon Pharmaceuticals Inc
Generálny riaditeľLonnel Coats
Zamestnanci81
Dátum založenia1995
Hlavné sídlo-
Odvetvie-